FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2913223653> ?p ?o ?g. }

• W2913223653 endingPage "1347" @default.
• W2913223653 startingPage "1337" @default.
• W2913223653 abstract "Aims Sodium glucose co‐transporter‐2 inhibitors have been shown to reduce cardiovascular events and heart failure in type 2 diabetic (T2D) patients with high cardiovascular risk. Dipeptidyl peptidase‐4 inhibitors showed neutral effects and may increase risk of heart failure. We aimed to compare cardiometabolic effects of dapagliflozin and vildagliptin in T2D patients with coronary artery disease (CAD). Methods Forty‐nine T2D patients with CAD were randomly assigned to dapagliflozin ( n = 25) or vildagliptin ( n = 24) for 6 months in a double‐blind fashion. Cardiometabolic parameters were collected at baseline and at the end of treatments. Results Mean age was 63.2 ± 7.9 years (female 46.9%). Baseline characteristics did not differ between two groups. At 6 months, HbA 1C significantly decreased in both dapaglifozin and vildagliptin groups (0.6 ± 1.0% vs 0.8 ± 1.4%, P = 0.22, respectively). There was no difference between the changes in lipid profiles. Body mass index decreased in patients receiving dapagliflozin, whereas it increased in those receiving vildagliptin (−1.27 [95% confidence interval −2.01, −0.53] vs 1.72 [0.72, 2.72] kg, P < 0.001). The reduction in systolic blood pressure and high‐sensitivity troponin T was observed in the dapagliflozin group (−9.87 [−18.00, −1.15] mmHg and 2.49 [−4.50, −0.47] pg/mL) but not in vildagliptin group (−1.97 [−9.42, 5.48] mmHg and 1.98 [−0.02, 3.97] pg/mL). The mean haemoglobin increased in the dapagliflozin group, whereas the mean platelet volume increased in the vildagliptin group. There was no significant change in the inflammatory markers in both the groups. Conclusions The extraglycaemic effects of dapagliflozin and vildagliptin on cardiometabolic parameters in T2D with CAD were different. The more favourable effects of dapagliflozin compared to vildagliptin may have explained the cardiovascular benefits observed only in sodium glucose co‐transporter‐2 inhibitors ." @default.
• W2913223653 created "2019-02-21" @default.
• W2913223653 creator A5000824289 @default.
• W2913223653 creator A5018447577 @default.
• W2913223653 creator A5025939163 @default.
• W2913223653 creator A5027749075 @default.
• W2913223653 creator A5073443185 @default.
• W2913223653 creator A5074956117 @default.
• W2913223653 creator A5078029455 @default.
• W2913223653 date "2019-04-13" @default.
• W2913223653 modified "2023-10-13" @default.
• W2913223653 title "Effects of dapagliflozin <i>vs</i> vildagliptin on cardiometabolic parameters in diabetic patients with coronary artery disease: a randomised study" @default.
• W2913223653 cites W1972226195 @default.
• W2913223653 cites W1978630848 @default.
• W2913223653 cites W1994914810 @default.
• W2913223653 cites W2001886262 @default.
• W2913223653 cites W2026480246 @default.
• W2913223653 cites W2028259155 @default.
• W2913223653 cites W2033493723 @default.
• W2913223653 cites W2064130493 @default.
• W2913223653 cites W2076471661 @default.
• W2913223653 cites W2080824382 @default.
• W2913223653 cites W2111069331 @default.
• W2913223653 cites W2120922908 @default.
• W2913223653 cites W2122077393 @default.
• W2913223653 cites W2126328471 @default.
• W2913223653 cites W2127854619 @default.
• W2913223653 cites W2138124374 @default.
• W2913223653 cites W2142830692 @default.
• W2913223653 cites W2146264128 @default.
• W2913223653 cites W2147663252 @default.
• W2913223653 cites W2147687575 @default.
• W2913223653 cites W2150855258 @default.
• W2913223653 cites W2150859826 @default.
• W2913223653 cites W2151683258 @default.
• W2913223653 cites W2153839551 @default.
• W2913223653 cites W2306356166 @default.
• W2913223653 cites W2331274940 @default.
• W2913223653 cites W2463902228 @default.
• W2913223653 cites W2475954707 @default.
• W2913223653 cites W2513040800 @default.
• W2913223653 cites W2564078202 @default.
• W2913223653 cites W2582603147 @default.
• W2913223653 cites W2587062523 @default.
• W2913223653 cites W2625462710 @default.
• W2913223653 cites W2626446274 @default.
• W2913223653 cites W2752749262 @default.
• W2913223653 cites W2765967569 @default.
• W2913223653 cites W2766306821 @default.
• W2913223653 cites W2771328536 @default.
• W2913223653 cites W2793292495 @default.
• W2913223653 cites W2794130465 @default.
• W2913223653 cites W2900413769 @default.
• W2913223653 doi "https://doi.org/10.1111/bcp.13903" @default.
• W2913223653 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6533436" @default.
• W2913223653 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30767253" @default.
• W2913223653 hasPublicationYear "2019" @default.
• W2913223653 type Work @default.
• W2913223653 sameAs 2913223653 @default.
• W2913223653 citedByCount "18" @default.
• W2913223653 countsByYear W29132236532020 @default.
• W2913223653 countsByYear W29132236532021 @default.
• W2913223653 countsByYear W29132236532022 @default.
• W2913223653 countsByYear W29132236532023 @default.
• W2913223653 crossrefType "journal-article" @default.
• W2913223653 hasAuthorship W2913223653A5000824289 @default.
• W2913223653 hasAuthorship W2913223653A5018447577 @default.
• W2913223653 hasAuthorship W2913223653A5025939163 @default.
• W2913223653 hasAuthorship W2913223653A5027749075 @default.
• W2913223653 hasAuthorship W2913223653A5073443185 @default.
• W2913223653 hasAuthorship W2913223653A5074956117 @default.
• W2913223653 hasAuthorship W2913223653A5078029455 @default.
• W2913223653 hasBestOaLocation W29132236531 @default.
• W2913223653 hasConcept C126322002 @default.
• W2913223653 hasConcept C126894567 @default.
• W2913223653 hasConcept C134018914 @default.
• W2913223653 hasConcept C164705383 @default.
• W2913223653 hasConcept C2776453732 @default.
• W2913223653 hasConcept C2777180221 @default.
• W2913223653 hasConcept C2777422806 @default.
• W2913223653 hasConcept C2778213512 @default.
• W2913223653 hasConcept C2779284873 @default.
• W2913223653 hasConcept C2780282729 @default.
• W2913223653 hasConcept C555293320 @default.
• W2913223653 hasConcept C71924100 @default.
• W2913223653 hasConcept C84393581 @default.
• W2913223653 hasConceptScore W2913223653C126322002 @default.
• W2913223653 hasConceptScore W2913223653C126894567 @default.
• W2913223653 hasConceptScore W2913223653C134018914 @default.
• W2913223653 hasConceptScore W2913223653C164705383 @default.
• W2913223653 hasConceptScore W2913223653C2776453732 @default.
• W2913223653 hasConceptScore W2913223653C2777180221 @default.
• W2913223653 hasConceptScore W2913223653C2777422806 @default.
• W2913223653 hasConceptScore W2913223653C2778213512 @default.
• W2913223653 hasConceptScore W2913223653C2779284873 @default.
• W2913223653 hasConceptScore W2913223653C2780282729 @default.
• W2913223653 hasConceptScore W2913223653C555293320 @default.
• W2913223653 hasConceptScore W2913223653C71924100 @default.

• next